 NEW YORK, Aug. 26, 2021 GLOBE NEWSWIRE -- Cellectis S.A. NASDAQ: CLLS EURONEXT GROWTH: ALCLS the Company, a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor CAR-T cells and gene therapy programs for monogenic diseases, today announced that management plans to participate in five virtual investor conferences. 